Glutamine, fatty liver disease and aging

Non-alcoholic fatty liver disease (NAFLD), characterized by the accumulation of hepatic fat due to non-alcoholic and non-viral causes, is the commonest form of chronic liver disease in western countries affecting over 25% of the worldwide population [1]. In spite of the epidemic proportions and gloomy future panorama of NAFLD, the causes and mechanisms underlying its progression are not completely understood and besides lifestyle interventions and weight loss by bariatric surgery, there are currently no approved therapies towards NAFLD.